- Former Citi President's Fund Up 84% This Year
- Qualcomm Outlook Misses Street, Samsung Deal Helps
- Fed to Maintain Low Rates Even as Economy Recovers
- Why the Dollar's Decline Doesn't Worry US Officials—Yet
- Nervous About US Stocks? Check Out Emerging Markets
- 3 Companies That Could Be Ripe For The Picking
- Kudlow: Stocks and Voters Show GOP the Way
- Former Merrill CEO Thain to Emerge From Seclusion
- Study Reveals What's Really Going on in Aisle Six
- Gold Will Hit $1,500 By June 2010: Strategist
- Crescenzi: Fed Conditions Its Commitment on Rates
- Three Way to Play the Dollar Carry Trade
- Study Reveals What's Really Going on in Aisle Six
- Time Warner Raises Forecast, Focuses on Exploiting Content
- Do You Buy Marchionne's Turnaround Plan?
- Call It 'Microsoft Math'
- Wells Fargo Bets on Housing Recovery
- Equities Are in a 'Definite Bullish Trend': Chief Investor
- Andersons shares fall on weak 3Q profit
- Eagle Bulk Shipping profit plummets
- States with jobless rates of 8.5 percent and above
- Corrections Corp. of America 3Q profit jumps
- Ohio casinos to hit Mich., Ind. gambling taxes
- Murphy Oil 3Q profit falls 68 percent
- Sanmina-SCI Corp. says worst of recession over
- Zumiez Oct. sales comparison drops 8.9 percent
- Microchip Technology declares dividend
Text Size 
SCOTTSDALE, Ariz. - Medicis Pharmaceutical Corp. posted a third-quarter profit on Wednesday, as sales of its skin products surged, and a research and development charge came off the books.
Medicis said it earned $21.1 million, or 33 cents per share. A year ago, the company lost $14.7 million, or 26 cents per share, partly due to a $30.5 million charge to acquire ongoing research after it invested in biotech drugmaker Revance Therapeutics.
Revenue jumped 32 percent, to $151.8 million from $115.4 million, due to stronger sales of its acne drug Solodyn and launch of its wrinkle remover Dysport.
Excluding one-time items it said its profit came to 50 cents per share in the most recent quarter.
Analysts, who typically exclude items, expected a profit of 42 cents per share and $153.2 million in revenue, according to Thomson Reuters.
Medicis said acne product revenue rose 61 percent to $106.8 million, and revenue from other skin products rose 4 percent to $35.5 million. Non-dermatology revenue fell 37 percent to $9.5 million.
The company raised its profit and revenue forecasts for the full year, calling for a profit of $1.56 to $1.60 per share. Three months ago, Medicis said it expected a profit of $1.42 to $1.57 per share. It raised its revenue outlook to a range of $561 million to $567 million, from $556 million to $574 million.
Analysts expect a profit of $1.56 per share and $565.3 million in revenue.
In the fourth quarter, Medicis said its spending will increase significantly as it conducts tests of the Liposonix system, which is designed to break up fat deposits in the stomach with ultrasound. Selling, general, and administrative costs will climb due to the launch of Dysport, the company added.
In total the company expects a profit of 58 cents per share to 62 cents per share, with $168 million to $174 million for the fourth quarter. Analysts expect 60 cents per share and revenue of $170.9 million.
In aftermarket trading, Medicis shares were unchanged at $21.73.
Print
Email
- The Oracle of Omaha is placing his bets on these 15 stocks, the biggest holdings of Berkshire Hathaway.
- The mass of man-made debris orbiting the Earth is dramatically increasing the risk of space collisions.
- Here are the world's most secretive tax havens, according to the Tax Justice Network.
- The Apple App Store's market dominance reaches a new milestone: 100,000 apps now available.
- A Harvard professor’s unusual confectionary is blowing away chocolatiers in Paris.
- One MIT graduate thinks you probably don’t smile enough, and she has invented a painful device to take care of that problem.
Data is a real-time snapshot *Data is delayed at least 15 minutes